louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06841549: The Relationship Between FAPI Results and Myocardial Fibrosis After Acute Myocardial Infarction
Official title: Prognostic Value of FAPI Results in Acute Myocardial Infarction After Successful Coronary Primary Intervention
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Myocardial Infarction (AMI)
Lead sponsor: The First Affiliated Hospital of Xiamen University
Sponsor class: OTHER
First posted: 2025-02-24
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: acute myocardial infarction after successful primary percutaneous intervention.

Brief summary: FAPI is a new method to discover the fibrosis of cardiac myocardium in some conditions, like myocardial infarction or cardiomyopathy. This purpose of this study is to find the relationship between FAPI results and myocardial fibrosis through some clinical serum inflammatory factors level. Meanwhile, it is the first time to provide the prognostic value of FAPI in the progression of acute myocardial infarction.


Eligibility criteria: Inclusion Criteria: acute myocardial infarction 1) after the successful primary intervention ;2) normal EF value; -

Exclusion Criteria: acute myocardial infarction 1) primary PCI failure; 2) EF reduced; 3) death during the hospitalization;

-

Primary outcomes:
measure: MACE
timeFrame: the first month, the third month, the half year and the next year after acute myocardial infarction
Secondary outcomes:
Other outcomes:
Locations:
city: Xiamen
country: China
facility: the First Affiliated Hospital of Xiamen University
state: Fujian
Study officials:
References:
citation: Zhang M, Quan W, Zhu T, Feng S, Huang X, Meng H, Du R, Zhu Z, Qu X, Li P, Cui Y, Shi K, Yan X, Zhang R, Li B. [68Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling. Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):839-848. doi: 10.1007/s00259-022-06015-0. Epub 2022 Nov 3.
Clinical trial NCT05372549: Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation
Official title: Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fertility Preservation
Lead sponsor: Clinique Ovo
Sponsor class: INDUSTRY
Collaborators: name: Ferring Pharmaceuticals
First posted: 2022-05-12
Enrollment: 179
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 37
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: OTHER

Brief summary: Whether it is for oncology or personal reasons, fertility preservation allows participants to preserve their oocytes (eggs) at their current age and condition for a better chance of having a baby in the future.

In order to proceed with fertility preservation, participants will need to undergo in vitro fertilization (IVF), which is standard practice, and take stimulation medication to stimulate production of more follicles.

The combination of both Rekovelle and Menopur for fertility preservation may increase ovarian response to stimulation and increase the number of oocytes retrieved to give better chances of embryos once the oocytes will be fertilized.

The goal in this study is to understand the effect of oxydative stress on the quality of oocytes.

For the purpose of the study and to evaluate this connection, serum levels of oxidative stress and cf-DNA in your blood will be measured.

Oocyte quality will also be assessed with Magenta, a prediction tool utilizing artificial intelligence (AI). This method is non-invasive and has no risks on the oocytes.


Eligibility criteria: Inclusion Criteria:

- Women 18 to 37 years of age inclusively eligible for fertility preservation for either social or oncology reason

Exclusion Criteria:

* Pregnancy and lactation
* Uncontrolled thyroid or adrenal dysfunction
* Tumours of the hypothalamus or pituitary gland
* Ovarian enlargement not due to polycystic ovarian syndrome
* Gynaecological haemorrhages of unknown aetiology
* Endometriosis stage III/IV
* Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle
* Use of Coenzyme Q10 during the stimulation cycle
* Renal and/or hepatic impairment
* Hypersensitivity to any active ingredient or excipients in follitropin delta and/or HP-hMG

Primary outcomes:
measure: Evaluate the correlation between the oxidative stress and the quality of oocytes
timeFrame: Change from baseline oxidative stress at the end of IVF controlled ovarian stimulaition
Secondary outcomes:
measure: Evaluation of oocyte quality by visualization
timeFrame: At the end of IVF stimulation
measure: Assessment of good quality oocytes
timeFrame: IVF stimulation cycle
measure: Number of mature oocytes retrieved
timeFrame: IVF stimulation cycle
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Olive Fertility Centre
state: British Columbia
city: Ottawa
country: Canada
facility: Ottawa Fertility Centre
state: Ontario
city: Montreal
country: Canada
facility: Clinique Ovo
state: Quebec
Study officials:
References:
Clinical trial NCT04418349: Evaluation of Posterior Component Separation Modified TAR Technique "Transversus Abdominids Release" in the Treatment of Parastomal Hernia
Official title: Evaluation of Posterior Component Separation Modified TAR Technique "Transversus Abdominids Release" in the Treatment of Parastomal Hernia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: TAR Technique
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2020-06-05
Enrollment: 30
Sex: ALL
Minimum age (years): 10
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Aim of the work In this study, we will evaluate posterior Evaluation of posterior component separation modified TAR technique "Transversus Abdominids Release" in the treatment of parastomal hernia. The primary outcome will be recurrence while the secondary outcome will be infection, postoperative complications (bleeding and dehiscence), pain score, operative time, hospitalization, need for drain, time for drain removal and pulmonary function test before and after surgery


Eligibility criteria: Inclusion Criteria:

* Adult patient fit for general anesthesia with parastomal herniation.

Exclusion Criteria:

* Patients who are unfit for general anaesthesia.
* Poor pulmonary function tests.
* Pregnant females.
* Patient younger than 18 years.
* Immunodeficiency.
* Patient with psychiatric disease disabling surgical intervention.

Primary outcomes:
measure: Recurrence rate
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura University
state: Dakahlia
Study officials:
References:
Clinical trial NCT04966949: Lateral Prostate Capsule Sparing Versus Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the Male
Official title: Lateral Prostate Capsule Sparing Versus Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the Male
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bladder Cancer
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital, Sun Yat-Sen University
name: Third Affiliated Hospital, Sun Yat-Sen University
name: The Seventh Affiliated Hospital of Sun Yat-sen University
First posted: 2021-07-19
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the perioperative, functional, and oncologic outcomes between nerve sparing and lateral prostate capsule sparing robot-assisted radical cystectomy with orthotopic ileal neobladder in male patients with bladder cancer.

Detailed description: This study will enroll male patients with bladder cancer who will undergo robot-assisted radical cystectomy with orthotopic ileal neobladder. The patients will be distributed into two comparable groups according to surgical procedures: nerve sparing group and lateral prostate capsule sparing group. Patient demographics and pathologic, perioperative, functional, and oncologic outcomes will be compared between the two groups.

Eligibility criteria: Inclusion Criteria:

1. Male patients aged 18 or older.
2. Patients those who are diagnosed with urothelial carcinoma.
3. Patients those who are without tumour in the bladder neck or urethra, and prostate cancer was ruled out by MRI and serum T-PSA\<2.5ng/ml.
4. Patients those who are capable of receiving radical cystectomy with orthotopic ileal neobladder.
5. Patients those who are able to cooperate and complete the follow-up.
6. Patients those who volunteer to participate in this study and sign the informed consens.

Exclusion Criteria:

1. Patients thsoe who are diagnosed distant metastasis before surgery.
2. Patients those who are diagnosed with other malignancies.
3. Patients those who had received pelvic radiotherapy or major pelvic operation.

Primary outcomes:
measure: day-time continence rate
timeFrame: 6 months
measure: night-time continence rate
timeFrame: 6 months
measure: postoperative sexual function
timeFrame: 6 months
Secondary outcomes:
measure: perioperative complication rate
timeFrame: 3 months
measure: operative time
timeFrame: 24 hours
measure: estimated blood loss
timeFrame: 24 hours
measure: overall survival
timeFrame: 1 year
measure: recurrence-free survival
timeFrame: 1 year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
name: Jian Huang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04116749: Gastric Emptying of Water in Obese Term Pregnant Women
Official title: Comparison of Gastric Emptying of Water in Obese vs. Non-obese Term Pregnant Women Undergoing Elective Cesarean Section
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Pregnancy Related
Lead sponsor: Kangbuk Samsung Hospital
Sponsor class: OTHER
First posted: 2019-10-07
Enrollment: 26
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Non laboring, term (≥37 weeks) pregnant women uldergoing elective cesarean section, in our medical center.

Brief summary: It has been believed that the risk of pulmonary aspiration in term pregnant women is increased, and should be considered that all term pregnant women to have "full stomach". Recently, gastric ultrasound has been adopted as a useful tool for quantitative and qualitative assessment of stomach before anesthesia, and predict the risk of pulmonary aspiration.

Although, both the obesity and pregnancy are known to be the risk of pulmonary aspiration, it is suggested in the American Society of Anesthesiology fasting guidelines, that the same fasting time should be applied in the obese and non-obese parturients. However, this was based on one study done in a small (10) numbers of volunteers.

Therefore, the investigators aimed to compare the gastric antral cross-sectional area in both obese and non-obese term pregnant women, scheduled for elective cesarean section.

Detailed description: This study is a prospective, observational study. 42 term (≥37 weeks) pregnant, non-laboring adult women scheduled for cesarean delivery will be included in the study. They will be allowed to drink water freely, until 2 hours before the anesthesia. Gastric ultrasound will be performed in 21 non-obese women, and 21 obese women. The obesity is defined by the body mass index at term.

Eligibility criteria: Inclusion Criteria:

* Non laboring, term (≥37 weeks) pregnant women
* Scheduled for elective cesarean section
* aged ≥ 18 years old
* American Society of Anesthesiology physical class 1-3

Exclusion Criteria:

* multigestational pregnancy
* diagnosed for delayed gastric emptying (GERD, gastrointestinal disease)
* diabetes

Primary outcomes:
measure: Gastric antral cross-sectional area
timeFrame: 2 hours after the time allowed to drink water.
Secondary outcomes:
measure: Preoperative anxiety
timeFrame: 2 hours after the time allowed to drink water.
measure: Hunger score
timeFrame: 2 hours after the time allowed to drink water.
measure: Thirst score
timeFrame: 2 hours after the time allowed to drink water.
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
Study officials:
affiliation: KangbukSamsung Hospital
name: Eunah Cho, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01076049: The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)
Official title: Evaluation of a Novel Solution, IrriSept, a New Delivery System, Containing a Long-acting Antimicrobial Agent for Irrigation of Skin and Soft Tissue Infections, in the Form of an Abscess in the Emergency Department: a Pilot Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Skin and Soft Tissue Infections
Abscess
Lead sponsor: Irrimax Corporation
Sponsor class: INDUSTRY
First posted: 2010-02-25
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The randomization methodology was controlled by a biostatistician at the site.
Primary purpose: OTHER

Brief summary: The purpose of this study was to determine whether Irrisept can effectively prevent the progression of skin and soft tissue infections (SSTIs) as compared to treatment by the current Standard of Care.

Detailed description: After being informed about the trial and potential risks, subjects completed an informed consent form prior to participation. After eligibility criteria was verified, an initial wound assessment examination was performed. Subjects were then randomized to the Irrisept or Standard of Care treatment group. Forty-eight hours later, wound progression and signs of infection were assessed.

Eligibility criteria: Inclusion Criteria:

1. Age 18 to 80
2. Skin and soft tissue infections (SSTIs), in the form of an abscess, which will require incision and drainage.
3. Patient able to provide an informed consent.
4. Patient volunteers to participate.

Exclusion Criteria:

1. Wound was caused by human or animal bite.
2. Wound is a blunt crush injury or has tendon, bone, or joint involvement.
3. Diabetic foot infection.
4. Anticipated incision size less than 5mm.
5. Abscess extends to the muscle layer.
6. Admission to hospital for any reason, including IV antibiotics.
7. Clinical signs of systemic infection on initial patient encounter.
8. Prior history of allergy or hypersensitivity to CHG.
9. Neutropenic (known ANC\<500/mm3), HIV (known CD4\<50), or other severely immunocompromised state (e.g., receiving chemotherapy).
10. Patient is diagnosed with systemic lupus erythematosus or other immunological disease.
11. Currently in police custody.
12. Patient withdraws from participation.
13. Patient unable or unwilling to give informed consent.

Primary outcomes:
measure: Wound State at 48-Hour Follow-up Visit
timeFrame: 48 hours
Secondary outcomes:
measure: Clinical Performance of Irrisept to the Current SoC
timeFrame: 48 hours
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Tampa General Hospital - University of South Florida
state: Florida
Study officials:
affiliation: Tampa General Hospital, University South Florida
name: David Wein, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04617249: Median and Paramedian Anesthesia in Cesarean Section
Official title: Assessment of Different Routes Median and Paramedian Anesthesia in Cesarean Section
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Anesthesia
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
First posted: 2020-11-05
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: anesthesia with median route versus paramedian route
Primary purpose: OTHER

Brief summary: The number of cesarean sections worldwide has markedly been increasing since 1985.Intrathecal anesthesia is preferred by most anesthesiologists over general anesthesia

Detailed description: Complications with spinal anesthesia are not common which makes it difficult to detect its incidence and one of the most serious complications is nerve injury.

Eligibility criteria: Inclusion Criteria:

* Age 18-42 years
* Scheduled for elective cesarean section
* ASA II

Exclusion Criteria:

* -Age \<18 years or \>42 years
* ASA \>II
* Emergency cesarean section

Primary outcomes:
measure: the number of women who will have less pain
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Aljazeera( Al Gazeera) hospital
Study officials:
affiliation: Algezeera hospitaland National Research Centre ,Egypt
name: Mahmoud Alalfy
role: STUDY_CHAIR
References:
Clinical trial NCT06187649: Infection After Implant-based Breast Reconstruction
Official title: A Systemic Review and Analysis of Factors and Outcomes in Breast Reconstruction
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Breast Implant Infection
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2024-01-02
Enrollment: 5000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Implant-based breast reconstruction following mastectomy

Brief summary: Infections following postmastectomy breast reconstruction can compromise surgical outcomes and lead to significant morbidity. The aim of this study was to determine factors associated with infection following two-stage implant-based reconstruction.


Eligibility criteria: Inclusion Criteria:

* Patients who received implant-based breast reconstruction following mastectomy between 2015 and 2020 in Seoul National University Hospital

Exclusion Criteria:

* Patients who received flap surgery simultaneously with implant insertion

Primary outcomes:
measure: Infection
timeFrame: 7 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06680349: Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
Official title: Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Fibrillary Glomerulonephritis
Keywords: fibrillary glomerulonephritis
anti-CD20
Lead sponsor: University of Turin, Italy
Sponsor class: OTHER
First posted: 2024-11-08
Enrollment: 21
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the clinical and histological effects of two rituximab-based regimens in fibrillary glomerulonephritis.


Eligibility criteria: Inclusion Criteria:

-Fibrillary glomerulonephritis (biospy proven defined by optical microscopy, immunofluorescence and electron microscopy studies with demonstration of the DNAJB9 protein)

Exclusion Criteria:

* previous treatment with anti-CD20; pregnant; unable to consent. other concomitant GN.

Primary outcomes:
measure: renal responce
timeFrame: 0, 3 and 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Torino
country: Italy
facility: San Giovanni Bosco Hub Hospital
Study officials:
References:
Clinical trial NCT02517749: Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management
Official title: Randomised Controlled Trial Comparing Outpatient Management of Malignant Pleural Effusion Via an Indwelling Pleural Catheter and Talc Pleurodesis Versus Standard Inpatient Management in Improving Health Related Quality of Life
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pleural Effusion, Malignant
Lead sponsor: Guy's and St Thomas' NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: Becton, Dickinson and Company
First posted: 2015-08-07
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multicentre randomised controlled trial evaluating global health related quality of life outcomes in patients with malignant pleural effusions. Patients will be randomised to receive either chest drain and talc pleurodesis or indwelling pleural catheter and talc pleurodesis. Patients will be followed up for 3 months post intervention


Eligibility criteria: Inclusion Criteria:

1. Diagnosis of malignant pleural effusion
2. WHO performance status 2 or less unless performance status is impaired by presence of effusion and likely to significantly improve with drainage
3. Expected survival greater than 3 months

Exclusion Criteria:

1. Age less than 18 years old
2. Pregnant or lactating
3. Known allergy to Talc or Lignocaine
4. Lack of symptomatic relief from effusion drainage
5. At least twice weekly drainage cannot be undertaken
6. Lymphoma or small cell carcinoma except\*:

   1. Failure of chemotherapy
   2. Deemed for palliative management
7. Non malignant effusions
8. Loculated pleural effusion
9. Unable to provide written informed consent to trial participation

Primary outcomes:
measure: Global health-related quality of life
timeFrame: 30 days
Secondary outcomes:
measure: Global health-related quality of life
timeFrame: 60 and 90 days
measure: Pleurodesis failure rate
timeFrame: 30, 60 and 90 days
measure: Improvement in symptoms of pain and breathlessness
timeFrame: 30, 60 and 90 days
measure: Complication rate
timeFrame: Day 7, 14, 30, 60 and 90
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Guy's and St Thomas' NHS Foundation Trust
Study officials:
References: